Eucrates Biomedical Acquisition Corp. Unit
EUCRU
EUCRU was delisted on the 26th of April, 2023.
0 hedge funds and large institutions have $0 invested in Eucrates Biomedical Acquisition Corp. Unit in 2023 Q2 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, reducing their positions, and 4 closing their positions.
100% less funds holding
Funds holding: 4 → 0 (-4)
100% less capital invested
Capital invested by funds: $6.72M → $0 (-$6.72M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 4
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Verition Fund Management
Greenwich,
Connecticut
|
-$4.12M |
| 2 |
SCM
Sio Capital Management
New York
|
-$2.58M |
| 3 |
CS
Clear Street
New York
|
-$28.4K |
| 4 |
DM
Deerfield Management
New York
|
-$10 |
EUCRU Hedge Fund Activity: Q2 2023 in Review
0 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Eucrates Biomedical Acquisition Corp. Unit (EUCRU) for Q2 2023, worth a combined $0 — down 100% from $6.72M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of EUCRU and 0 opened new positions — a net loss of 4 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Verition Fund Management, exiting entirely with an estimated $4.12M sold.
- 0 institutional investors held Eucrates Biomedical Acquisition Corp. Unit (EUCRU) as of Q2 2023, down from 4 in Q1 2023.
- Funds reported $0 of Eucrates Biomedical Acquisition Corp. Unit stock for Q2 2023, down 100% quarter-over-quarter.
- 0 funds opened new Eucrates Biomedical Acquisition Corp. Unit positions in Q2 2023 and 4 closed out, a net change of -4 holders.
- The largest Eucrates Biomedical Acquisition Corp. Unit seller in Q2 2023 was Verition Fund Management, an estimated $4.12M sold.
Based on aggregated 13F filings for Q2 2023.